Duration of immunity produced by a live attenuated vaccine against avian pneumovirus type C

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


A recently developed live, attenuated vaccine against avian pneumovirus (APV) was found to be safe and protective in experimental birds. Duration of immunity following a single dose of this experimental vaccine in 1-week-old turkey poults is described. Two groups each of 60 poults were housed in separate isolation rooms. Birds in group one were inoculated oculonasally at 1 week of age with the vaccine. The second group served as a non-vaccinated group and was inoculated with mock-infected cell culture fluid. At 3, 7, 10, and 14 weeks post vaccination, 15 birds from each of the groups were removed to separate isolation rooms and challenged with virulent APV. Taken together, data on clinical signs and virus detection in choanal swabs following each challenge indicated that the vaccine was able to protect birds for up to 14 weeks post vaccination. Peak antibody levels were attained 7 weeks post vaccination and declined thereafter. These results indicated that this experimental vaccine induced protection against APV even in the absence of high antibody titres.

Original languageEnglish (US)
Pages (from-to)465-469
Number of pages5
JournalAvian Pathology
Issue number5
StatePublished - 2004

Bibliographical note

Funding Information:
This study was supported in part by grants from Rapid Agricultural Response Fund and Minnesota Turkey Research and Promotion Council. The assistance provided by Dr Claudia Munoz-Zanzi is gratefully acknowledged.


Dive into the research topics of 'Duration of immunity produced by a live attenuated vaccine against avian pneumovirus type C'. Together they form a unique fingerprint.

Cite this